t(8;9)(p22;p24)/PCM1-JAK2 Activates SOCS2 and SOCS3 via STAT5

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Ehrentraut, Stefan ^a   Nagel, Stefan ^a   Scherr, Michaela E ^b   Schneider, Björn ^c   Quentmeier, Hilmar ^a   Geffers, Robert ^d   Kaufmann, Maren ^a   Meyer, Corinna ^a   Prochorec Sobieszek, Monika ^e   Ketterling, Rhett P ^f   Knudson, Ryan A ^f   Feldman, Andrew L ^f   Kadin, Marshall E ^g   Drexler, Hans G ^a   MacLeod, Roderick A F ^a  

^a LEIBNIZ INSTITUTE DSMZ GERMAN COLLECTION OF MICROORGANISMS AND CELL CULTURES   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF ROSTOCK   (Germany)

^d HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^e INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^f MAYO CLINIC   (United States)

^g BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; LENTIVIRUS VECTOR; N TERT BUTYL 3 [5 METHYL 2 [4 [2 (1 PYRROLIDINYL)ETHOXY]PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 2; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSCRIPTION FACTOR GATA 3;

ARTICLE; CELL STRAIN MAC 1; CELL STRAIN MAC 2A; CELL STRAIN MAC 2B; CHROMOSOME 8P; CHROMOSOME 9P; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DISEASE COURSE; EOSINOPHILIC LEUKEMIA; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC REGULATION; GENETIC TRANSCRIPTION; GENOME; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UPREGULATION;

CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 8; CHROMOSOMES, HUMAN, PAIR 9; GATA3 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENETIC VECTORS; HUMANS; LENTIVIRUS; LYMPHOMA, T-CELL, CUTANEOUS; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS; PYRROLIDINES; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; STAT5 TRANSCRIPTION FACTOR; SULFONAMIDES; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TRANSLOCATION, GENETIC;

EID: 84872776180     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053767     Document Type: Article

References (50)

1. Hoeller S, Walz C, Reiter A, Dirnhofer S, Tzankov A, (2011) PCM1-JAK2-fusion: a potential treatment target in myelodysplastic-myeloproliferative and other hemato-lymphoid neoplasms. Expert Opin Ther Targets 15: 53-62.
2. Chen E, Staudt LM, Green AR, (2012) Janus kinase deregulation in leukemia and lymphoma. Immunity 36: 529-541.
3. Radtke S, Haan S, Jorissen A, Hermanns HM, Diefenbach S, et al. (2005) The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression. J Biol Chem 280: 25760-25768.
4. Dawson MA, Bannister AJ, Gottgens B, Foster SD, Bartke T, et al. (2009) JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 461: 819-822.
5. Lu X, Levine R, Tong W, Wernig G, Pikman Y, et al. (2005) Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A 102: 18962-18967.
6. Bochtler T, Kirsch M, Maier B, Bachmann J, Klingmuller U, et al. (2012) Centrosomal targeting of tyrosine kinase activity does not enhance oncogenicity in chronic myeloproliferative disorders. Leukemia 26: 728-735.
7. Adelaide J, Perot C, Gelsi-Boyer V, Pautas C, Murati A, et al. (2006) A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma. Leukemia 20: 536-537.
8. Ho JM, Beattie BK, Squire JA, Frank DA, Barber DL, (1999) Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling. Blood 93: 4354-4364.
9. Lacronique V, Boureux A, Monni R, Dumon S, Mauchauffe M, et al. (2000) Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood 95: 2076-2083.
10. Schwaller J, Frantsve J, Aster J, Williams IR, Tomasson MH, et al. (1998) Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J 17: 5321-5333.
11. Scherr M, Battmer K, Blomer U, Schiedlmeier B, Ganser A, et al. (2002) Lentiviral gene transfer into peripheral blood-derived CD34+ NOD/SCID-repopulating cells. Blood 99: 709-712.
12. Scherr M, Battmer K, Ganser A, Eder M, (2003) Modulation of gene expression by lentiviral-mediated delivery of small interfering RNA. Cell Cycle 2: 251-257.
13. MacLeod RA, Nagel S, Scherr M, Schneider B, Dirks WG, et al. (2008) Human leukemia and lymphoma cell lines as models and resources. Curr Med Chem 15: 339-359.
14. Drexler HG (2000) The Leukemia-Lymphoma Cell Lines FactsBook. San Diego: Academic Press.
15. Davis TH, Morton CC, Miller-Cassman R, Balk SP, Kadin ME, (1992) Hodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone. N Engl J Med 326: 1115-1122.
16. Kadin ME, Cavaille-Coll MW, Gertz R, Massague J, Cheifetz S, et al. (1994) Loss of receptors for transforming growth factor beta in human T-cell malignancies. Proc Natl Acad Sci U S A 91: 6002-6006.
17. Prochorec-Sobieszek M, Nasilowska-Adamska B, Borg K, Kopec I, Kos-Zakrzewska K, et al. (2012) Chronic eosinophilic leukemia with erythroblastic proliferation and the rare translocation t(8;9)(p22;p24) with PCM1-JAK2 fusion gene: a distinct clinical, pathological and genetic entity with potential treatment target? Leuk Lymphoma 53: 18241827.
18. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, et al. (2011) Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 29: 789-796.
19. Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, et al. (2011) The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 117: 3421-3429.
20. MacLeod RA, Kaufmann M, Drexler HG, (2007) Cytogenetic harvesting of commonly used tumor cell lines. Nat Protoc 2: 372-382.
21. Smyth GK (2005) Limma: linear models for microarray data. In: Gentleman RC, V.; Dudoit, S.; Irizarry, R.; Huber, W., editor. Bioinformatics and Computational Biology Solutions using R and Bioconductor. New York: Springer. pp. 397-420.
22. Quentmeier H, Geffers R, Jost E, Macleod RA, Nagel S, et al. (2008) SOCS2: inhibitor of JAK2V617F-mediated signal transduction. Leukemia 22: 2169-2175.
23. Tefferi A, (2012) JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood 119: 2721-2730.
24. Lierman E, Selleslag D, Smits S, Billiet J, Vandenberghe P, (2012) Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia. Blood 120: 1529-1531.
25. Harrison C, Verstovsek S, McMullin MF, Mesa R, (2012) Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure? Br J Haematol 157: 426-437.
26. Quentmeier H, MacLeod RA, Zaborski M, Drexler HG, (2006) JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 20: 471-476.
27. Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, et al. (1997) A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278: 1309-1312.
28. Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, et al. (1997) Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 90: 2535-2540.
29. Schwaller J, Parganas E, Wang D, Cain D, Aster JC, et al. (2000) Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol Cell 6: 693-704.
30. Vidal OM, Merino R, Rico-Bautista E, Fernandez-Perez L, Chia DJ, et al. (2007) In vivo transcript profiling and phylogenetic analysis identifies suppressor of cytokine signaling 2 as a direct signal transducer and activator of transcription 5b target in liver. Mol Endocrinol 21: 293-311.
31. Knosp CA, Carroll HP, Elliott J, Saunders SP, Nel HJ, et al. (2011) SOCS2 regulates T helper type 2 differentiation and the generation of type 2 allergic responses. J Exp Med 208: 1523-1531.
32. Babon JJ, Kershaw NJ, Murphy JM, Varghese LN, Laktyushin A, et al. (2012) Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. Immunity 36: 239-250.
33. Croker BA, Kiu H, Nicholson SE, (2008) SOCS regulation of the JAK/STAT signalling pathway. Semin Cell Dev Biol 19: 414-422.
34. Piessevaux J, Lavens D, Peelman F, Tavernier J, (2008) The many faces of the SOCS box. Cytokine Growth Factor Rev 19: 371-381.
35. Brender C, Nielsen M, Kaltoft K, Mikkelsen G, Zhang Q, et al. (2001) STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. Blood 97: 1056-1062.
36. Irino T, Uemura M, Yamane H, Umemura S, Utsumi T, et al. (2011) JAK2 V617F-dependent upregulation of PU.1 expression in the peripheral blood of myeloproliferative neoplasm patients. PLoS One 6: e22148.
37. Lejeune D, Demoulin JB, Renauld JC, (2001) Interleukin 9 induces expression of three cytokine signal inhibitors: cytokine-inducible SH2-containing protein, suppressor of cytokine signalling (SOCS)-2 and SOCS-3, but only SOCS-3 overexpression suppresses interleukin 9 signalling. Biochem J 353: 109-116.
38. Brender C, Lovato P, Sommer VH, Woetmann A, Mathiesen AM, et al. (2005) Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNalpha. Leukemia 19: 209-213.
39. Schultheis B, Carapeti-Marootian M, Hochhaus A, Weisser A, Goldman JM, et al. (2002) Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism. Blood 99: 1766-1775.
40. Hansen N, Agerstam H, Wahlestedt M, Landberg N, Askmyr M, et al. (2012) SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell function. Leukemia (in press).
41. Favre H, Benhamou A, Finidori J, Kelly PA, Edery M, (1999) Dual effects of suppressor of cytokine signaling (SOCS-2) on growth hormone signal transduction. FEBS Lett 453: 63-66.
42. Tannahill GM, Elliott J, Barry AC, Hibbert L, Cacalano NA, et al. (2005) SOCS2 can enhance interleukin-2 (IL-2) and IL-3 signaling by accelerating SOCS3 degradation. Mol Cell Biol 25: 9115-9126.
43. Greenhalgh CJ, Rico-Bautista E, Lorentzon M, Thaus AL, Morgan PO, et al. (2005) SOCS2 negatively regulates growth hormone action in vitro and in vivo. J Clin Invest 115: 397-406.
44. Hookham MB, Elliott J, Suessmuth Y, Staerk J, Ward AC, et al. (2007) The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood 109: 4924-4929.
45. Hosoya T, Maillard I, Engel JD, (2010) From the cradle to the grave: activities of GATA-3 throughout T-cell development and differentiation. Immunol Rev 238: 110-125.
46. Sundrud MS, Grill SM, Ni D, Nagata K, Alkan SS, et al. (2003) Genetic reprogramming of primary human T cells reveals functional plasticity in Th cell differentiation. J Immunol 171: 3542-3549.
47. Abraham RM, Zhang Q, Odum N, Wasik MA, (2011) The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma. Cancer Biol Ther 12.
48. Krejsgaard T, Ralfkiaer U, Clasen-Linde E, Eriksen KW, Kopp KL, et al. (2011) Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway. J Invest Dermatol 131: 1331-1338.
49. Ellinghaus D, Ellinghaus E, Nair RP, Stuart PE, Esko T, et al. (2012) Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet 90: 636-647.
50. Fridman JS, Scherle PA, Collins R, Burn T, Neilan CL, et al. (2011) Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. J Invest Dermatol 131: 1838-1844.